The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
Abstract
PURPOSE: To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with advanced hepatocellular carcinoma (HCC). METHODS: ASCO convened an Expert Panel to conduct a systematic review of published phase III randomized controlled trials (2007-2020) on systemic therapy for advanced HCC and provide recommended care options for this patient population. RESULTS: Nine phase III randomized controlled trials met the inclusion criteria. RECOMMENDATIONS: Atezolizumab + bevacizumab (atezo + bev) may be offered as first-line treatment of most patients with advanced HCC, Child-Pugh class A liver disease, Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1, and following management of esophageal varices, when present, according to institutional guidelines. Where there are contraindications to atezolizumab and/or bevacizumab, tyrosine kinase inhibitors sorafenib or lenvatinib may be offered as first-line treatment of patients with advanced HCC, Child-Pugh class A liver disease, and ECOG PS 0-1. Following first-line treatment with atezo + bev, and until better data are available, second-line therapy with a tyrosine kinase inhibitor may be recommended for appropriate candidates. Following first-line therapy with sorafenib or lenvatinib, second-line therapy options for appropriate candidates include cabozantinib, regorafenib for patients who previously tolerated sorafenib, or ramucirumab (for patients with α-fetoprotein ≥ 400 ng/mL), or atezo + bev where patients did not have access to this option as first-line therapy. Pembrolizumab or nivolumab are also reasonable options for appropriate patients following sorafenib or lenvatinib. Consideration of nivolumab + ipilimumab as an option for second-line therapy and third-line therapy is discussed. Further guidance on choosing between therapy options is included within the guideline. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Cochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Villanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Forner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Self-citationCabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B.-Y., Cicin, I., Merle, P., Chen, Y., Park, J.-W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,344
Self-citationFerrell, B. R., Temel, J. S., Temin, S., Alesi, E. R., Balboni, T. A., Basch, E. M., Firn, J. I., Paice, J. A., Peppercorn, J. M., Phillips, T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1474 · Cited by 2,117
(1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-5-642_1 · Cited by 2,081
Global Burden of Disease Liver Cancer Collaboration, Akinyemiju, T., Abera, S., Ahmed, M., Alam, N., Alemayohu, M. A., Allen, C., Al-Raddadi, R., Alvis-Guzman, N., Amoako, Y., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3055 · Cited by 1,987
Finn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01307 · Cited by 1,789
Self-citationZhu, A. X., Kang, Y.-K., Yen, C.-J., Finn, R. S., Galle, P. R., Llovet, J. M., Assenat, E., Brandi, G., Pracht, M., Lim, H. Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30937-9 · Cited by 1,662
Self-citationPhase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Abou-Alfa, G. K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A., De Greve, J., Douillard, J.-Y., Lathia, C., Schwartz, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3441 · Cited by 1,195
Self-citationFinancial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer
Ramsey, S. D., Bansal, A., Fedorenko, C. R., Blough, D. K., Overstreet, K. A., Shankaran, V., & Newcomb, P. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.6620 · Cited by 912
Zhu, A. X., Park, J. O., Ryoo, B.-Y., Yen, C.-J., Poon, R., Pastorelli, D., Blanc, J.-F., Chung, H. C., Baron, A. D., Pfiffer, T. E. F., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00050-9 · Cited by 846
Self-citationKudo, M., Ueshima, K., Ikeda, M., Torimura, T., Tanabe, N., Aikata, H., Izumi, N., Yamasaki, T., Nojiri, S., Hino, K., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318934 · Cited by 721
Yau, T., Park, J. W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Han, K.-H., Harding, J. J., Merle, P., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.029 · Cited by 647
Self-citationAmerican Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Meropol, N. J., Schrag, D., Smith, T. J., Mulvey, T. M., Langdon, R. M., Blum, D., Ubel, P. A., & Schnipper, L. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1183 · Cited by 638
Patient-clinician communication: American Society of Clinical Oncology consensus guideline
Gilligan, T., Coyle, N., Frankel, R. M., Berry, D. L., Bohlke, K., Epstein, R. M., Finlay, E., Jackson, V. A., Lathan, C. S., Loprinzi, C. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2311 · Cited by 610
Bruix, J., Cheng, A.-L., Meinhardt, G., Nakajima, K., De Sanctis, Y., & Llovet, J. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.06.026 · Cited by 562
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Dusetzina, S. B., Winn, A. N., Abel, G. A., Huskamp, H. A., & Keating, N. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.9123 · Cited by 500
Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030
Petrick, J. L., Kelly, S. P., Altekruse, S. F., McGlynn, K. A., & Rosenberg, P. S. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.7412 · Cited by 442
Marrero, J. A., Kudo, M., Venook, A. P., Ye, S.-L., Bronowicki, J.-P., Chen, X.-P., Dagher, L., Furuse, J., Geschwind, J.-F. H., de Guevara, L. L., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.020 · Cited by 385
Finn, R. S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Gerolami, R., Caparello, C., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.04.010 · Cited by 347
Brożek, J. L., Akl, E. A., Compalati, E., Kreis, J., Terracciano, L., Fiocchi, A., Ueffing, E., Andrews, J., Alonso-Coello, P., Meerpohl, J. J., et al. (2011) · Allergy · doi:10.1111/j.1398-9995.2010.02530.x · Cited by 297
Kim, R. D., Sarker, D., Meyer, T., Yau, T., Macarulla, T., Park, J.-W., Choo, S. P., Hollebecque, A., Sung, M. W., Lim, H.-Y., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0555 · Cited by 262
Self-citationArtinyan, A., Mailey, B., Sanchez‐Luege, N., Khalili, J., Sun, C., Bhatia, S., Wagman, L. D., Nissen, N., Colquhoun, S. D., & Kim, J. (2010) · Cancer · doi:10.1002/cncr.24817 · Cited by 250
Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions
Streeter, S. B., Schwartzberg, L., Husain, N., & Johnsrud, M. (2011) · Journal of Oncology Practice · doi:10.1200/jop.2011.000316 · Cited by 248
Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma
Rich, N. E., Hester, C., Odewole, M., Murphy, C. C., Parikh, N. D., Marrero, J. A., Yopp, A. C., & Singal, A. G. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.05.039 · Cited by 214
Disparities in liver cancer occurrence in the United States by race/ethnicity and state
Islami, F., Miller, K. D., Siegel, R. L., Fedewa, S. A., Ward, E. M., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21402 · Cited by 207
Miller, A. A., Murry, D. J., Owzar, K., Hollis, D. R., Kennedy, E. B., Abou-Alfa, G., Desai, A., Hwang, J., Villalona-Calero, M. A., Dees, E. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0931 · Cited by 206
Self-citationShiffman, R. N., Michel, G., Rosenfeld, R. M., & Davidson, C. (2012) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000172 · Cited by 184
Treatment Satisfaction and Adherence to Oral Chemotherapy in Patients With Cancer
Jacobs, J. M., Pensak, N. A., Sporn, N. J., MacDonald, J. J., Lennes, I. T., Safren, S. A., Pirl, W. F., Temel, J. S., & Greer, J. A. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2016.019729 · Cited by 162
Jackson, R., Psarelli, E., Berhane, S., Khan, H., & Johnson, P. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.5197 · Cited by 153
Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond
Kudo, M. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i7.789 · Cited by 148
Mathur, A. K., Osborne, N. H., Lynch, R., Ghaferi, A. A., Dimick, J. B., & Sonnenday, C. J. (2010) · Archives of Surgery · doi:10.1001/archsurg.2010.272 · Cited by 146
Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
Sanoff, H. K., Chang, Y., Lund, J. L., O’Neil, B. H., & Dusetzina, S. B. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0478 · Cited by 139
Ha, J. Y., Yan, M., Aguilar, M. E. F., Bhuket, T. P., Tana, M. M.-S., Liu, B., Gish, R. G., & Wong, R. J. (2016) · Cancer · doi:10.1002/cncr.30103 · Cited by 108
McNamara, M. G., Slagter, A. E., Nuttall, C., Frizziero, M., Pihlak, R., Lamarca, Á., Tariq, N., Valle, J. W., Hubner, R. A., Knox, J. J., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.031 · Cited by 107
Self-citationKambhampati, S., Bauer, K., Bracci, P. M., Keenan, B. P., Behr, S. C., Gordan, J. D., & Kelley, R. K. (2019) · Cancer · doi:10.1002/cncr.32206 · Cited by 105
Self-citationMuluneh, B., Schneider, M., Faso, A., Amerine, L. B., Daniels, R., Crisp, B., Valgus, J. M., & Savage, S. (2018) · Journal of Oncology Practice · doi:10.1200/jop.17.00039 · Cited by 103
Kelley, R. K., Sangro, B., Harris, W. P., Ikeda, M., Okusaka, T., Kang, Y., Qin, S., Tai, W. M. D., Lim, H. Y., Yau, T. C. C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4508 · Cited by 100
Self-citationParikh, N. D., Marshall, V. D., Singal, A. G., Nathan, H., Lok, A. S.-F., Balkrishnan, R., & Shahinian, V. B. (2016) · Hepatology · doi:10.1002/hep.28881 · Cited by 91
Parikh, N. D., Singal, A. G., & Hutton, D. W. (2017) · Cancer · doi:10.1002/cncr.30863 · Cited by 85
Kobayashi, M., Kudo, M., Izumi, N., Kaneko, S., Azuma, M. K., Copher, R. M., Meier, G., Pan, J., Ishii, M., & Ikeda, S. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01554-0 · Cited by 84
Health care costs associated with hepatocellular carcinoma: A population-based study
Thein, H., Isaranuwatchai, W., Campitelli, M. A., Feld, J. J., Yoshida, E. M., Sherman, M., Hoch, J. S., Peacock, S. J., Krahn, M. D., & Earle, C. C. (2013) · Hepatology · doi:10.1002/hep.26231 · Cited by 80
Shlomai, A., Leshno, M., & Goldstein, D. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207132 · Cited by 57
Paolella, G., Boyd, A., Wirth, S., Cuéllar, S., Venepalli, N. K., & Crawford, S. Y. (2018) · Pharmacy · doi:10.3390/pharmacy6010023 · Cited by 55
Self-citationLiao, W., Huang, J., Hutton, D. W., Zhu, G., Wu, Q., Wen, F., Bai, L., & Li, Q. (2019) · Liver International · doi:10.1111/liv.14257 · Cited by 55
Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma
Soto‐Pérez‐de‐Celis, E., Aguiar, P. N., Cordon, M. L., Chávarri-Guerra, Y., & Lopes, G. D. L., Jr. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7275 · Cited by 44
He, A. R., Yau, T. C. C., Hsu, C., Kang, Y., Kim, T., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.512 · Cited by 36
Self-citationGalle, P. R., Finn, R. S., Qin, S., Ikeda, M., Zhu, A. X., Kim, T., Kudo, M., Breder, V. V., Merle, P., Kaseb, A. O., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.476 · Cited by 35
Self-citationCost-effectiveness of Sorafenib for Treatment of Advanced Hepatocellular Carcinoma in India
Gupta, N. M., Verma, R. K., Prinja, S., & Dhiman, R. K. (2018) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2018.10.003 · Cited by 27
Hirao, C., Mikoshiba, N., Shibuta, T., Yamahana, R., Kawakami, A., Tateishi, R., Yamaguchi, H., Koike, K., & Yamamoto‐Mitani, N. (2017) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx087 · Cited by 26
Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis
Shlomai, A., Leshno, M., & Goldstein, D. A. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819878304 · Cited by 23
Labeur, T. A., ten Cate, D. W. G., Takkenberg, R. B., Azahaf, H., van Oijen, M. G. H., van Delden, O. M., de Man, R. A., van Vugt, J. L. A., IJzermans, J. N. M., Eskens, F. A. L. M., et al. (2018) · Acta Oncologica · doi:10.1080/0284186x.2018.1479070 · Cited by 15
Elsisi, G. H., Nada, Y., Rashad, N., & Carapinha, J. L. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1552432 · Cited by 15
Cited by
BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update
Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.018 · Cited by 4,319
Self-citationImmunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
Self-citationAdvances in immunotherapy for hepatocellular carcinoma
Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00438-0 · Cited by 1,306
Singal, A. G., Kanwal, F., & Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00825-3 · Cited by 951
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 727
Self-citation
Metadata
- Authors
- Gordan, J. D., Kennedy, E. B., Abou-Alfa, G. K., Beg, M. S., Brower, S. T., Gade, T. P., Goff, L., Gupta, S., Guy, J., Harris, W. P., Iyer, R., Jaiyesimi, I., Jhawer, M., Karippot, A., Kaseb, A. O., Kelley, R. K., Knox, J. J., Kortmansky, J., Leaf, A., Remak, W. M., Shroff, R. T., Sohal, D. P. S., Taddei, T. H., Venepalli, N. K., Wilson, A., Zhu, A. X., & Rose, M. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-12-20
- Volume
- 38
- Issue
- 36
- Pages
- 4317-4345
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3100629716
- Cited by
- 570
- References
- 63
- FWCI
- 44.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.